Kanta Subbarao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8001099/publications.pdf

Version: 2024-02-01

267	30,077	5248	6113
papers	citations	83 h-index	159 g-index

291	291	291	30968
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 1205-1211.	15.2	3,133
2	Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. Journal of Experimental Medicine, 2011, 208, 181-193.	4.2	775
3	Systems biology of vaccination for seasonal influenza in humans. Nature Immunology, 2011, 12, 786-795.	7.0	749
4	An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nature Medicine, 2004, 10, 871-875.	15.2	679
5	Genetic Characterization of the Pathogenic Influenza A/Goose/Guangdong/1/96 (H5N1) Virus: Similarity of Its Hemagglutinin Gene to Those of H5N1 Viruses from the 1997 Outbreaks in Hong Kong. Virology, 1999, 261, 15-19.	1.1	636
6	A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature, 2004, 428, 561-564.	13.7	633
7	Influenza. Lancet, The, 1999, 354, 1277-1282.	6.3	609
8	Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. Journal of Virological Methods, 2004, 121, 85-91.	1.0	591
9	Influenza. Lancet, The, 2017, 390, 697-708.	6.3	550
10	Predicting the Evolution of Human Influenza A. Science, 1999, 286, 1921-1925.	6.0	444
11	pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGN. Journal of Virology, 2004, 78, 5642-5650.	1.5	442
12	A Mouse-Adapted SARS-Coronavirus Causes Disease and Mortality in BALB/c Mice. PLoS Pathogens, 2007, 3, e5.	2.1	428
13	Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. Journal of Clinical Investigation, 2010, 120, 1663-1673.	3.9	403
14	Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice. Journal of Virology, 2004, 78, 3572-3577.	1.5	400
15	Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nature Medicine, 2020, 26, 1428-1434.	15.2	400
16	Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6641-6646.	3.3	390
17	Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9804-9809.	3.3	372
18	Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4⁺T Cells Are Important in Control of SARS-CoV Infection. Journal of Virology, 2010, 84, 1289-1301.	1.5	367

#	Article	IF	Citations
19	A Severe Acute Respiratory Syndrome Coronavirus That Lacks the E Gene Is Attenuated In Vitro and In Vivo. Journal of Virology, 2007, 81, 1701-1713.	1.5	354
20	SARS-CoV-2 Variants and Vaccines. New England Journal of Medicine, 2021, 385, 179-186.	13.9	322
21	Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nature Communications, 2021, 12, 1162.	5.8	316
22	Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12121-12126.	3.3	312
23	Mechanisms of Host Defense following Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) Pulmonary Infection of Mice. Journal of Immunology, 2004, 173, 4030-4039.	0.4	306
24	Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12123-12128.	3.3	276
25	Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters. Journal of Virology, 2005, 79, 503-511.	1.5	270
26	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell, 2016, 166, 609-623.	13.5	270
27	Influenza Vaccines: Challenges and Solutions. Cell Host and Microbe, 2015, 17, 295-300.	5.1	261
28	Evaluation of candidate vaccine approaches for MERS-CoV. Nature Communications, 2015, 6, 7712.	5.8	258
29	Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and Ferrets. PLoS Medicine, 2006, 3, e360.	3.9	257
30	Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet, The, 2004, 363, 2122-2127.	6.3	252
31	Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses. Science Immunology, 2017, 2, .	5.6	252
32	Evaluation of a Genetically Modified Reassortant H5N1 Influenza A Virus Vaccine Candidate Generated by Plasmid-Based Reverse Genetics. Virology, 2003, 305, 192-200.	1.1	243
33	The Immunobiology of SARS. Annual Review of Immunology, 2007, 25, 443-472.	9.5	242
34	Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host and Microbe, 2016, 19, 800-813.	5.1	238
35	Identification and Characterization of Severe Acute Respiratory Syndrome Coronavirus Replicase Proteins. Journal of Virology, 2004, 78, 9977-9986.	1.5	236
36	Scientific barriers to developing vaccines against avian influenza viruses. Nature Reviews Immunology, 2007, 7, 267-278.	10.6	225

#	Article	IF	Citations
37	Glycosylation at 158N of the Hemagglutinin Protein and Receptor Binding Specificity Synergistically Affect the Antigenicity and Immunogenicity of a Live Attenuated H5N1 A/Vietnam/1203/2004 Vaccine Virus in Ferrets. Journal of Virology, 2010, 84, 6570-6577.	1.5	224
38	Neuraminidase Stalk Length and Additional Glycosylation of the Hemagglutinin Influence the Virulence of Influenza H5N1 Viruses for Mice. Journal of Virology, 2009, 83, 4704-4708.	1.5	221
39	Respiratory Virus Infections: Understanding COVID-19. Immunity, 2020, 52, 905-909.	6.6	217
40	Chasing Seasonal Influenza â€" The Need for a Universal Influenza Vaccine. New England Journal of Medicine, 2018, 378, 7-9.	13.9	213
41	Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology, 2004, 330, 8-15.	1.1	209
42	Genetic characterization of H3N2 influenza viruses isolated from pigs in North America, 1977â€"1999: evidence for wholly human and reassortant virus genotypes. Virus Research, 2000, 68, 71-85.	1.1	202
43	Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcÎ³RII-dependent entry into B cells in vitro. Vaccine, 2007, 25, 729-740.	1.7	197
44	Aged BALB/c Mice as a Model for Increased Severity of Severe Acute Respiratory Syndrome in Elderly Humans. Journal of Virology, 2005, 79, 5833-5838.	1.5	189
45	The PB2 Subunit of the Influenza Virus RNA Polymerase Affects Virulence by Interacting with the Mitochondrial Antiviral Signaling Protein and Inhibiting Expression of Beta Interferon. Journal of Virology, 2010, 84, 8433-8445.	1.5	187
46	Prophylactic and Therapeutic Efficacy of Human Monoclonal Antibodies against H5N1 Influenza. PLoS Medicine, 2007, 4, e178.	3.9	185
47	Molecular Correlates of Influenza A H5N1 Virus Pathogenesis in Mice. Journal of Virology, 2000, 74, 10807-10810.	1.5	183
48	Eurasian-Origin Gene Segments Contribute to the Transmissibility, Aerosol Release, and Morphology of the 2009 Pandemic H1N1 Influenza Virus. PLoS Pathogens, 2011, 7, e1002443.	2.1	172
49	Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. Journal of Infectious Diseases, 2015, 212, 702-710.	1.9	158
50	Characterization of the Surface Proteins of Influenza A (H5N1) Viruses Isolated from Humans in 1997â€"1998. Virology, 1999, 254, 115-123.	1.1	157
51	Animal models for SARS and MERS coronaviruses. Current Opinion in Virology, 2015, 13, 123-129.	2.6	156
52	Antigenic Fingerprinting of H5N1 Avian Influenza Using Convalescent Sera and Monoclonal Antibodies Reveals Potential Vaccine and Diagnostic Targets. PLoS Medicine, 2009, 6, e1000049.	3.9	155
53	DNA Vaccine Expressing Conserved Influenza Virus Proteins Protective Against H5N1 Challenge Infection in Mice. Emerging Infectious Diseases, 2002, 8, 796-801.	2.0	153
54	Development of Effective Vaccines against Pandemic Influenza. Immunity, 2006, 24, 5-9.	6.6	151

#	Article	IF	Citations
55	Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology, 2005, 340, 174-182.	1.1	149
56	A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial. Journal of Infectious Diseases, 2013, 207, 957-965.	1.9	147
57	Development and Characterization of a Severe Acute Respiratory Syndromeâ€“Associated Coronavirusâ€“Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice. Journal of Infectious Diseases, 2005, 191, 507-514.	1.9	146
58	Evaluation of Human Monoclonal Antibody 80R for Immunoprophylaxis of Severe Acute Respiratory Syndrome by an Animal Study, Epitope Mapping, and Analysis of Spike Variants. Journal of Virology, 2005, 79, 5900-5906.	1.5	145
59	Reappearance and Global Spread of Variants of Influenza B/Victoria/2/87 Lineage Viruses in the 2000â€“2001 and 2001â€“2002 Seasons. Virology, 2002, 303, 1-8.	1.1	144
60	SARS-CoV Pathogenesis Is Regulated by a STAT1 Dependent but a Type I, II and III Interferon Receptor Independent Mechanism. PLoS Pathogens, 2010, 6, e1000849.	2.1	139
61	Animal models and vaccines for SARS-CoV infection. Virus Research, 2008, 133, 20-32.	1.1	136
62	Emerging Respiratory Viruses: Challenges and Vaccine Strategies. Clinical Microbiology Reviews, 2006, 19, 614-636.	5.7	134
63	The soft palate is an important site of adaptation for transmissible influenza viruses. Nature, 2015, 526, 122-125.	13.7	133
64	Molecular Determinants of Severe Acute Respiratory Syndrome Coronavirus Pathogenesis and Virulence in Young and Aged Mouse Models of Human Disease. Journal of Virology, 2012, 86, 884-897.	1.5	132
65	Recombinant Influenza A Virus Vaccines for the Pathogenic Human A/Hong Kong/97 (H5N1) Viruses. Journal of Infectious Diseases, 1999, 179, 1132-1138.	1.9	131
66	Influenza A Virus Assembly Intermediates Fuse in the Cytoplasm. PLoS Pathogens, 2014, 10, e1003971.	2.1	128
67	Polygenic virulence factors involved in pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice. Virus Research, 2007, 128, 159-163.	1.1	119
68	The Open Reading Frame 3a Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Promotes Membrane Rearrangement and Cell Death. Journal of Virology, 2010, 84, 1097-1109.	1.5	119
69	Vaccines for Pandemic Influenza. Emerging Infectious Diseases, 2006, 12, 66-72.	2.0	116
70	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Reports Medicine, 2021, 2, 100208.	3.3	115
71	A Live Attenuated Severe Acute Respiratory Syndrome Coronavirus Is Immunogenic and Efficacious in Golden Syrian Hamsters. Journal of Virology, 2008, 82, 7721-7724.	1.5	112
72	Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine, 2009, 27, 4953-4960.	1.7	109

#	Article	IF	Citations
73	Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	109
74	Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine. ACS Nano, 2022, 16, 11769-11780.	7.3	108
75	Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nature Reviews Immunology, 2020, 20, 727-738.	10.6	107
76	Is there an ideal animal model for SARS?. Trends in Microbiology, 2006, 14, 299-303.	3.5	105
77	Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology, 2005, 334, 160-165.	1.1	104
78	Consensus summary report for CEPI/BC March 12â€“13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine, 2020, 38, 4783-4791.	1.7	102
79	Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4592-4597.	3.3	99
80	Therapy with a Severe Acute Respiratory Syndromeâ€“Associated Coronavirusâ€“Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters. Journal of Infectious Diseases, 2006, 193, 685-692.	1.9	95
81	In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Neglected Tropical Diseases, 2017, 11, e0005584.	1.3	94
82	Immunohistochemical and In Situ Hybridization Studies of Influenza A Virus Infection in Human Lungs. American Journal of Clinical Pathology, 2000, 114, 227-233.	0.4	91
83	Avian Influenza H6 Viruses Productively Infect and Cause Illness in Mice and Ferrets. Journal of Virology, 2008, 82, 10854-10863.	1.5	91
84	Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19. Nature Communications, 2020, 11, 5703.	5.8	90
85	A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine, 2009, 27, 3744-3753.	1.7	87
86	The Multibasic Cleavage Site of the Hemagglutinin of Highly Pathogenic A/Vietnam/1203/2004 (H5N1) Avian Influenza Virus Acts as a Virulence Factor in a Host-Specific Manner in Mammals. Journal of Virology, 2012, 86, 2706-2714.	1.5	87
87	A Live Attenuated Influenza A(H5N1) Vaccine Induces Long-Term Immunity in the Absence of a Primary Antibody Response. Journal of Infectious Diseases, 2014, 209, 1860-1869.	1.9	87
88	Evaluation of Replication and Pathogenicity of Avian Influenza A H7 Subtype Viruses in a Mouse Model. Journal of Virology, 2007, 81, 10558-10566.	1.5	86
89	Generation and Protective Ability of Influenza Virusâ€“Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge. Journal of Infectious Diseases, 2016, 214, 945-952.	1.9	84
90	Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)â€“Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection. Journal of Infectious Diseases, 2016, 213, 1557-1561.	1.9	84

#	Article	IF	Citations
91	H5N1 vaccines in humans. Virus Research, 2013, 178, 78-98.	1.1	83
92	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infectious Diseases, The, 2021, 21, 1383-1394.	4.6	82
93	Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus. Virology, 2015, 479-480, 247-258.	1.1	80
94	Encephalitis Associated with Influenza B Virus Infection in 2 Children and a Review of the Literature. Clinical Infectious Diseases, 2003, 36, e87-e95.	2.9	77
95	The contribution of animal models to the understanding of the host range and virulence of influenza A viruses. Microbes and Infection, 2011, 13, 502-515.	1.0	75
96	Immune imprinting and SARS-CoV-2 vaccine design. Trends in Immunology, 2021, 42, 956-959.	2.9	73
97	Reassortment and evolution of current human influenza A and B viruses. Virus Research, 2004, 103, 55-60.	1.1	72
98	A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology, 2008, 378, 123-132.	1.1	71
99	A Single-Amino-Acid Substitution in a Polymerase Protein of an H5N1 Influenza Virus Is Associated with Systemic Infection and Impaired T-Cell Activation in Mice. Journal of Virology, 2009, 83, 11102-11115.	1.5	69
100	Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody. PLoS Pathogens, 2017, 13, e1006565.	2.1	69
101	Avian Influenza Virus Glycoproteins Restrict Virus Replication and Spread through Human Airway Epithelium at Temperatures of the Proximal Airways. PLoS Pathogens, 2009, 5, e1000424.	2.1	68
102	A Live Attenuated H9N2 Influenza Vaccine Is Well Tolerated and Immunogenic in Healthy Adults. Journal of Infectious Diseases, 2009, 199, 711-716.	1.9	68
103	Vaccination with DNA encoding internal proteins of influenza virus does not require CD8+ cytotoxic T lymphocytes: either CD4+ or CD8+ T cells can promote survival and recovery after challenge. International Immunology, 2000, 12, 91-101.	1.8	67
104	Innate and adaptive T cells in influenza disease. Frontiers of Medicine, 2018, 12, 34-47.	1.5	67
105	The success of SARS-CoV-2 vaccines and challenges ahead. Cell Host and Microbe, 2021, 29, 1111-1123.	5.1	67
106	Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine, 2014, 32, 6798-6804.	1.7	65
107	Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nature Communications, 2021, 12, 1403.	5.8	65
108	Antibody Pressure by a Human Monoclonal Antibody Targeting the 2009 Pandemic H1N1 Virus Hemagglutinin Drives the Emergence of a Virus with Increased Virulence in Mice. MBio, 2012, 3, .	1.8	63

#	Article	IF	Citations
109	Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology, 2003, 308, 270-278.	1.1	62
110	H5N1 Viruses and Vaccines. PLoS Pathogens, 2007, 3, e40.	2.1	60
111	Immunogenicity and Protective Efficacy in Mice and Hamsters of a Î²-Propiolactone Inactivated Whole Virus SARS-CoV Vaccine. Viral Immunology, 2010, 23, 509-519.	0.6	59
112	B Cell Response and Hemagglutinin Stalk-Reactive Antibody Production in Different Age Cohorts following 2009 H1N1 Influenza Virus Vaccination. Vaccine Journal, 2013, 20, 867-876.	3.2	59
113	Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets. Vaccine, 2016, 34, 563-570.	1.7	59
114	Intercontinental Circulation of Human Influenza A(H1N2) Reassortant Viruses during the 2001â€“2002 Influenza Season. Journal of Infectious Diseases, 2002, 186, 1490-1493.	1.9	58
115	Pause on Avian Flu Transmission Research. Science, 2012, 335, 400-401.	6.0	58
116	Live Attenuated Influenza Vaccine. Current Topics in Microbiology and Immunology, 2014, 386, 181-204.	0.7	58
117	Influenza A Virus Infection Complicated by Fatal Myocarditis. American Journal of Forensic Medicine and Pathology, 2000, 21, 375-379.	0.4	58
118	Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. Vaccine, 2003, 21, 1974-1979.	1.7	57
119	The Ferret Model for Influenza. Current Protocols in Microbiology, 2009, 13, Unit 15G.2.	6.5	57
120	Development of a High-Yield Live Attenuated H7N9 Influenza Virus Vaccine That Provides Protection against Homologous and Heterologous H7 Wild-Type Viruses in Ferrets. Journal of Virology, 2014, 88, 7016-7023.	1.5	57
121	Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1140-1145.	3.3	56
122	Comparative Study of Influenza Virus Replication in MDCK Cells and in Primary Cells Derived from Adenoids and Airway Epithelium. Journal of Virology, 2012, 86, 11725-11734.	1.5	56
123	The prospects and challenges of universal vaccines for influenza. Trends in Microbiology, 2013, 21, 350-358.	3.5	56
124	Ferrets as Models for Influenza Virus Transmission Studies and Pandemic Risk Assessments. Emerging Infectious Diseases, 2018, 24, 965-971.	2.0	56
125	Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting. Journal of Infectious Diseases, 2020, 222, 1280-1288.	1.9	56
126	Human seasonal influenza A viruses induce H7N9-cross-reactive antibody-dependent cellular cytotoxicity (ADCC) antibodies that are directed towards the nucleoprotein. Journal of Infectious Diseases, 2017, 215, jiw629.	1.9	55

#	Article	IF	Citations
127	Comparison of Seroconversion in Children and Adults With Mild COVID-19. JAMA Network Open, 2022, 5, e221313.	2.8	55
128	Influenza virus vaccines: lessons from the 2009 H1N1 pandemic. Current Opinion in Virology, 2011, 1, 254-262.	2.6	54
129	Evaluation of Live Attenuated Influenza A Virus H6 Vaccines in Mice and Ferrets. Journal of Virology, 2009, 83, 65-72.	1.5	53
130	Engineering H5N1 avian influenza viruses to study human adaptation. Nature, 2012, 486, 335-340.	13.7	53
131	Immune Responses to Avian Influenza Viruses. Journal of Immunology, 2019, 202, 382-391.	0.4	53
132	Molecular aspects of avian influenza (H5N1) viruses isolated from humans. Reviews in Medical Virology, 2000, 10, 337-348.	3.9	52
133	Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology, 2007, 366, 166-173.	1.1	51
134	A 12-Monthâ€“Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response. Journal of Infectious Diseases, 2016, 214, 832-835.	1.9	51
135	Strand-Specific Dual RNA Sequencing of Bronchial Epithelial Cells Infected with Influenza A/H3N2 Viruses Reveals Splicing of Gene Segment 6 and Novel Host-Virus Interactions. Journal of Virology, 2018, 92, .	1.5	51
136	The Mouse Model for Influenza. Current Protocols in Microbiology, 2009, 13, Unit 15G.3.	6.5	50
137	A Live Attenuated H7N7 Candidate Vaccine Virus Induces Neutralizing Antibody That Confers Protection from Challenge in Mice, Ferrets, and Monkeys. Journal of Virology, 2010, 84, 11950-11960.	1.5	50
138	Comparison of Heterosubtypic Protection in Ferrets and Pigs Induced by a Single-Cycle Influenza Vaccine. Journal of Immunology, 2018, 200, 4068-4077.	0.4	50
139	Genomic Analysis Reveals Age-Dependent Innate Immune Responses to Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 2008, 82, 9465-9476.	1.5	49
140	Lymphopenia Associated with Highly Virulent H5N1 Virus Infection Due to Plasmacytoid Dendritic Cellâ€“Mediated Apoptosis of T Cells. Journal of Immunology, 2014, 192, 5906-5912.	0.4	49
141	Nonreplicating Influenza A Virus Vaccines Confer Broad Protection against Lethal Challenge. MBio, 2015, 6, e01487-15.	1.8	48
142	The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses. Journal of Infectious Diseases, 2017, 216, 356-365.	1.9	46
143	Moving On Out: Transport and Packaging of Influenza Viral RNA into Virions. Annual Review of Virology, 2016, 3, 411-427.	3.0	45
144	Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9). Journal of Infectious Diseases, 2016, 213, 922-929.	1.9	45

#	Article	IF	Citations
145	Preclinical development of a molecular clampâ€stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2. Clinical and Translational Immunology, 2021, 10, e1269.	1.7	45
146	Severity of Clinical Disease and Pathology in Ferrets Experimentally Infected with Influenza Viruses Is Influenced by Inoculum Volume. Journal of Virology, 2014, 88, 13879-13891.	1.5	43
147	High-Affinity H7 Head and Stalk Domainâ€“Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine. Journal of Infectious Diseases, 2015, 212, 1270-1278.	1.9	43
148	Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines. Npj Vaccines, 2017, 2, 35.	2.9	43
149	SARS Vaccine Protective in Mice. Emerging Infectious Diseases, 2005, 11, 1312-1314.	2.0	42
150	Evaluation of Replication and Cross-Reactive Antibody Responses of H2 Subtype Influenza Viruses in Mice and Ferrets. Journal of Virology, 2010, 84, 7695-7702.	1.5	42
151	An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine, 1997, 15, 1372-1378.	1.7	40
152	Live Attenuated and Inactivated Influenza Vaccines in Children. Journal of Infectious Diseases, 2015, 211, 352-360.	1.9	40
153	Comparison of a Live Attenuated 2009 H1N1 Vaccine with Seasonal Influenza Vaccines against 2009 Pandemic H1N1 Virus Infection in Mice and Ferrets. Journal of Infectious Diseases, 2011, 203, 930-936.	1.9	39
154	Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. Virology, 2010, 406, 80-87.	1.1	38
155	An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Vaccine, 2011, 29, 3144-3148.	1.7	38
156	An openâ€label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza and Other Respiratory Viruses, 2013, 7, 66-73.	1.5	38
157	Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9430-9435.	3.3	38
158	Avian influenza H7N9 viruses: a rare second warning. Cell Research, 2018, 28, 1-2.	5.7	38
159	Attacking the flu: Neutralizing antibodies may lead to 'universal' vaccine. Nature Medicine, 2009, 15, 1251-1252.	15.2	37
160	Effect of Priming with H1N1 Influenza Viruses of Variable Antigenic Distances on Challenge with 2009 Pandemic H1N1 Virus. Journal of Virology, 2012, 86, 8625-8633.	1.5	37
161	Safety, immunogencity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in mice and ferrets. Virology, 2010, 398, 109-114.	1.1	36
162	Correlates of Immunity to Influenza as Determined by Challenge of Children with Live, Attenuated Influenza Vaccine. Open Forum Infectious Diseases, 2016, 3, ofw108.	0.4	36

#	Article	IF	Citations
163	In Vivo Imaging of Influenza Virus Infection in Immunized Mice. MBio, 2017, 8, .	1.8	36
164	Vaccines for older adults. BMJ, The, 2021, 372, n188.	3.0	36
165	Performance of Rapid Tests for Detection of Avian Influenza A Virus Types H5N1 and H9N2. Journal of Clinical Microbiology, 2006, 44, 1596-1597.	1.8	35
166	Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. Cell Reports, 2021, 37, 109822.	2.9	35
167	Integrating genotypes and phenotypes improves long-term forecasts of seasonal influenza A/H3N2 evolution. ELife, 2020, 9, .	2.8	35
168	Transmission Studies Resume for Avian Flu. Science, 2013, 339, 520-521.	6.0	34
169	The Contribution of Systemic and Pulmonary Immune Effectors to Vaccine-Induced Protection from H5N1 Influenza Virus Infection. Journal of Virology, 2012, 86, 5089-5098.	1.5	33
170	In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice. Journal of Virology, 2017, 91, .	1.5	33
171	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight, 2021, 6, .	2.3	33
172	Can Immunity Induced by the Human Influenza Virus N1 Neuraminidase Provide Some Protection from Avian Influenza H5N1 Viruses?. PLoS Medicine, 2007, 4, e91.	3.9	32
173	The Magnitude of Local Immunity in the Lungs of Mice Induced by Live Attenuated Influenza Vaccines Is Determined by Local Viral Replication and Induction of Cytokines. Journal of Virology, 2011, 85, 76-85.	1.5	32
174	The Matrix Gene Segment Destabilizes the Acid and Thermal Stability of the Hemagglutinin of Pandemic Live Attenuated Influenza Virus Vaccines. Journal of Virology, 2014, 88, 12374-12384.	1.5	32
175	Potent Vesicular Stomatitis Virus-Based Avian Influenza Vaccines Provide Long-Term Sterilizing Immunity against Heterologous Challenge. Journal of Virology, 2010, 84, 4611-4618.	1.5	30
176	An Adjuvant for the Induction of Potent, Protective Humoral Responses to an H5N1 Influenza Virus Vaccine with Antigen-Sparing Effect in Mice. Journal of Virology, 2010, 84, 8639-8649.	1.5	30
177	The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. Vaccine, 2012, 30, 2516-2522.	1.7	30
178	Replication and Immunogenicity of Swine, Equine, and Avian H3 Subtype Influenza Viruses in Mice and Ferrets. Journal of Virology, 2013, 87, 6901-6910.	1.5	30
179	Mammalian Adaptation in the PB2 Gene of Avian H5N1 Influenza Virus. Journal of Virology, 2013, 87, 10884-10888.	1.5	30
180	Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes. Journal of Virology, 2018, 92, .	1.5	30

#	Article	IF	Citations
181	Cellular targets for influenza drugs. Nature Biotechnology, 2010, 28, 239-240.	9.4	29
182	A Simple Restriction Fragment Length Polymorphism-Based Strategy That Can Distinguish the Internal Genes of Human H1N1, H3N2, and H5N1 Influenza A Viruses. Journal of Clinical Microbiology, 2000, 38, 2579-2583.	1.8	29
183	A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine, 2021, 74, 103729.	2.7	29
184	African Green Monkeys Recapitulate the Clinical Experience with Replication of Live Attenuated Pandemic Influenza Virus Vaccine Candidates. Journal of Virology, 2014, 88, 8139-8152.	1.5	28
185	Robust correlations across six SARSâ€CoVâ€2 serology assays detecting distinct antibody features. Clinical and Translational Immunology, 2021, 10, e1258.	1.7	28
186	BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial). BMJ Open, 2021, 11, e052101.	0.8	27
187	Vesicular Stomatitis Virus-Based H5N1 Avian Influenza Vaccines Induce Potent Cross-Clade Neutralizing Antibodies in Rhesus Macaques. Journal of Virology, 2011, 85, 4602-4605.	1.5	26
188	Animal Models for Sars. Advances in Experimental Medicine and Biology, 2006, 581, 463-471.	0.8	26
189	Are there alternative avian influenza viruses for generation of stable attenuated avian-human influenza A reassortant viruses?. Virus Research, 1995, 39, 105-118.	1.1	25
190	The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus. Virology, 2009, 395, 280-288.	1.1	25
191	Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms. Expert Review of Vaccines, 2014, 13, 873-883.	2.0	25
192	Boosted Influenza-Specific T Cell Responses after H5N1 Pandemic Live Attenuated Influenza Virus Vaccination. Frontiers in Immunology, 2015, 6, 287.	2.2	25
193	Transcriptional and epi-transcriptional dynamics of SARS-CoV-2 during cellular infection. Cell Reports, 2021, 35, 109108.	2.9	25
194	Molecular Epidemiology of Influenza A(H3N2) Virus Reinfections. Journal of Infectious Diseases, 2002, 185, 980-985.	1.9	24
195	Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for Severe Acute Respiratory Syndrome coronavirus (SARS-CoV). Vaccine, 2007, 25, 2173-2179.	1.7	24
196	DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial. PLoS ONE, 2018, 13, e0206837.	1.1	24
197	Live Attenuated Vaccines for Pandemic Influenza. Current Topics in Microbiology and Immunology, 2009, 333, 109-132.	0.7	24
198	Classical swine H1N1 influenza viruses confer cross protection from swine-origin 2009 pandemic H1N1 influenza virus infection in mice and ferrets. Virology, 2010, 408, 128-133.	1.1	23

#	Article	IF	Citations
199	Heterovariant Cross-Reactive B-Cell Responses Induced by the 2009 Pandemic Influenza Virus A Subtype H1N1 Vaccine. Journal of Infectious Diseases, 2013, 207, 288-296.	1.9	23
200	Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance. Open Forum Infectious Diseases, 2021, 8, ofab239.	0.4	23
201	Influenza Vaccines: Present and Future. Advances in Virus Research, 1999, 54, 349-373.	0.9	22
202	The Ongoing Battle Against Influenza: The challenge of flu transmission. Nature Medicine, 2012, 18, 1468-1470.	15.2	21
203	Receptor specificity does not affect replication or virulence of the 2009 pandemic H1N1 influenza virus in mice and ferrets. Virology, 2013, 446, 349-356.	1.1	21
204	H5N1 Vaccine-Specific B Cell Responses in Ferrets Primed with Live Attenuated Seasonal Influenza Vaccines. PLoS ONE, 2009, 4, e4436.	1.1	21
205	Offâ€target effects of bacillus Calmetteâ€“GuÃ©rin vaccination on immune responses to SARSâ€CoVâ€2: implications for protection against severe COVIDâ€19. Clinical and Translational Immunology, 2022, 11, e1387.	1.7	21
206	Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028811.	2.3	19
207	Evaluation of Three Live Attenuated H2 Pandemic Influenza Vaccine Candidates in Mice and Ferrets. Journal of Virology, 2014, 88, 2867-2876.	1.5	18
208	The Critical Interspecies Transmission Barrier at the Animalâ€“Human Interface. Tropical Medicine and Infectious Disease, 2019, 4, 72.	0.9	18
209	Humans and Ferrets with Prior H1N1 Influenza Virus Infections Do Not Exhibit Evidence of Original Antigenic Sin after Infection or Vaccination with the 2009 Pandemic H1N1 Influenza Virus. Vaccine Journal, 2014, 21, 737-746.	3.2	17
210	Pathogenesis, Humoral Immune Responses, and Transmission between Cohoused Animals in a Ferret Model of Human Respiratory Syncytial Virus Infection. Journal of Virology, 2018, 92, .	1.5	17
211	COVID-19 vaccines: time to talk about the uncertainties. Nature, 2020, 586, 475-475.	13.7	17
212	A Tale of Two Mutations: Beginning to Understand the Problems with Egg-Based Influenza Vaccines?. Cell Host and Microbe, 2019, 25, 773-775.	5.1	16
213	SARS-CoV-2: A New Song Recalls an Old Melody. Cell Host and Microbe, 2020, 27, 692-694.	5.1	16
214	The Temperature-Sensitive and Attenuation Phenotypes Conferred by Mutations in the Influenza Virus PB2, PB1, and NP Genes Are Influenced by the Species of Origin of the PB2 Gene in Reassortant Viruses Derived from Influenza A/California/07/2009 and A/WSN/33 Viruses. Journal of Virology, 2014, 88, 12339-12347.	1.5	15
215	Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers. Clinical Infectious Diseases, 2021, 72, 2035-2041.	2.9	15
216	Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines. JCI Insight, 2019, 4, .	2.3	15

#	Article	IF	Citations
217	Antigen-activated dendritic cells ameliorate influenza A infections. Journal of Clinical Investigation, 2013, 123, 2850-2861.	3.9	15
218	Locally Acquired Human Infection with Swine-Origin Influenza A(H3N2) Variant Virus, Australia, 2018. Emerging Infectious Diseases, 2020, 26, 143-147.	2.0	14
219	Convalescent plasma treatment for COVIDâ€19: Tempering expectations with the influenza experience. European Journal of Immunology, 2020, 50, 1447-1453.	1.6	14
220	Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine. Drugs, 2018, 78, 1297-1308.	4.9	13
221	Persistence of SARS-CoV-2â€“Specific IgG in Children 6 Months After Infection, Australia. Emerging Infectious Diseases, 2021, 27, 2233-2235.	2.0	13
222	Evaluation of replication, immunogenicity and protective efficacy of a live attenuated cold-adapted pandemic H1N1 influenza virus vaccine in non-human primates. Vaccine, 2012, 30, 5603-5610.	1.7	12
223	Robustness of the Ferret Model for Influenza Risk Assessment Studies: a Cross-Laboratory Exercise. MBio, 2022, 13, .	1.8	12
224	A Live Attenuated Equine H3N8 Influenza Vaccine Is Highly Immunogenic and Efficacious in Mice and Ferrets. Journal of Virology, 2015, 89, 1652-1659.	1.5	11
225	Evaluation of the Biological Properties and Cross-Reactive Antibody Response to H10 Influenza Viruses in Ferrets. Journal of Virology, 2017, 91, .	1.5	11
226	How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines. Journal of Infectious Diseases, 2019, 219, S81-S87.	1.9	11
227	Detection of adamantane-sensitive influenza A(H3N2) viruses in Australia, 2017: a cause for hope?. Eurosurveillance, 2017, 22, .	3.9	11
228	Opposing Effects of Prior Infection versus Prior Vaccination on Vaccine Immunogenicity against Influenza A(H3N2) Viruses. Viruses, 2022, 14, 470.	1.5	11
229	Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. Journal of Experimental Medicine, 2011, 208, 411-411.	4.2	9
230	A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets. Journal of Virology, 2015, 89, 6907-6917.	1.5	9
231	Refining the approach to vaccines against influenza A viruses with pandemic potential. Future Virology, 2015, 10, 1033-1047.	0.9	9
232	Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses. Journal of Virology, 2017, 91, .	1.5	9
233	Live Attenuated Cold-Adapted Influenza Vaccines. Cold Spring Harbor Perspectives in Medicine, 2020, 11, a038653.	2.9	9
234	Memory CD4+ T cells: beyond â€œhelperâ€•functions. Journal of Clinical Investigation, 2012, 122, 2768-2770.	3.9	9

#	Article	IF	Citations
235	Long-Read RNA Sequencing Identifies Polyadenylation Elongation and Differential Transcript Usage of Host Transcripts During SARS-CoV-2 In Vitro Infection. Frontiers in Immunology, 2022, 13, 832223.	2.2	9
236	Roadblocks to translational challenges on viral pathogenesis. Nature Medicine, 2013, 19, 30-34.	15.2	7
237	Respiratory Virus Vaccines. , 2015, , 1129-1170.		7
238	Replication of live attenuated cold-adapted H2N2 influenza virus vaccine candidates in non human primates. Vaccine, 2015, 33, 193-200.	1.7	7
239	Passive immunization with influenza haemagglutinin specific monoclonal antibodies. Human Vaccines and Immunotherapeutics, 2018, 14, 1-9.	1.4	7
240	Influenza Viruses. , 2012, , 1149-1159.e7.		7
241	Influenza vaccination and prevention of cardiovascular disease mortality â€“ Authors' reply. Lancet, The, 2018, 391, 427-428.	6.3	6
242	Age-related differences in SARS-CoV-2 binding factors: An explanation for reduced susceptibility to severe COVID-19 among children?. Paediatric Respiratory Reviews, 2022, 44, 61-69.	1.2	6
243	ACE2 Expression in Organotypic Human Airway Epithelial Cultures and Airway Biopsies. Frontiers in Pharmacology, 2022, 13, 813087.	1.6	6
244	Epidemiological Data on the Effectiveness of Influenza Vaccineâ€"Another Piece of the Puzzle. Journal of Infectious Diseases, 2018, 218, 176-178.	1.9	5
245	Influenza Viruses. , 2008, , 1130-1138.		5
246	H5N2 vaccine viruses on Russian and US live attenuated influenza virus backbones demonstrate similar infectivity, immunogenicity and protection in ferrets. Vaccine, 2018, 36, 1871-1879.	1.7	4
247	The role of animal models in influenza vaccine research. , 2008, , 161-202.		4
248	Influenza a infections: from chickens to humans. Clinical Microbiology Newsletter, 2001, 23, 9-13.	0.4	3
249	Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia. Viruses, 2021, 13, 1618.	1.5	3
250	A case report describing the immune response of an infant with congenital heart disease and severe COVID-19. Communications Medicine, 2021, 1, .	1.9	3
251	The Pandemic Threat of Avian Influenza Viruses. Perspectives in Medical Virology, 2006, 16, 97-132.	0.1	2
252	Influenza vaccineâ€"live. , 2013, , 294-311.		2

#	Article	IF	Citations
253	Advances in Influenza Virus Research: A Personal Perspective. Viruses, 2018, 10, 724.	1.5	2
254	Influenza Vaccineâ€"Live. , 2018, , 489-510.e7.		2
255	Fibrin clot characteristics and anticoagulant response in a SARSâ€CoVâ€2â€infected endothelial model. EJHaem, 2022, 3, 326-334.	0.4	2
256	An addition to treatment options for avian influenza A H5N1?. Lancet Infectious Diseases, The, 2015, 15, 251-253.	4.6	1
257	Live Attenuated Influenza Vaccines for Pandemic Preparedness. Journal of the Pediatric Infectious Diseases Society, 2020, 9, S15-S18.	0.6	1
258	Temporal differences in culturable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) from the respiratory and gastrointestinal tracts in a patient with moderate coronavirus disease 2019 (COVID-19). Infection Control and Hospital Epidemiology, 2022, 43, 1286-1288.	1.0	1
259	The Role of Animal Models In Influenza Vaccine Research. , 2011, , 223-272.		1
260	What influenza activity can we anticipate in 2022?. Medical Journal of Australia, 2022, 216, 239-241.	0.8	1
261	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. Expert Review of Vaccines, 2022, 21, 1055-1070.	2.0	1
262	Development and evaluation of candidate influenza a vaccines for pandemic preparedness. International Congress Series, 2004, 1263, 813-817.	0.2	0
263	New options to treat influenza B. Nature Microbiology, 2017, 2, 1342-1343.	5.9	0
264	Infants Harness the Germline against RSV. Immunity, 2018, 48, 190-192.	6.6	0
265	A second external quality assessment of isolation and identification of influenza viruses in cell culture in the Asia Pacific region highlights improved performance by participating laboratories. Journal of Clinical Virology, 2021, 142, 104907.	1.6	0
266	The Development of Live-Attenuated Vaccines for Pandemic Influenza. , 2010, , 423-430.		0
267	Induction of protective immunity against influenza A/Jiangxi-Donghu/346/2013 (H10N8) in mice. Journal of General Virology, 2017, 98, 155-165.	1.3	0